MRSN - Mersana Therapeutics, Inc.
| Previous Close | 3.8400 |
| Open | 3.8900 |
| Bid | 3.9100 x 800 |
| Ask | 8.5000 x 800 |
| Day's Range | 3.8800 - 4.1400 |
| 52 Week Range | 2.8450 - 20.3100 |
| Volume | 242,760 |
| Avg. Volume | 196,522 |
| Market Cap | 187.05M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.2030 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.25 |
- GlobeNewswire•6 days ago
Mersana Therapeutics Announces Appointment of Brian C. DeSchuytner as Senior Vice President of Finance and Product Strategy
Mersana Therapeutics, Inc. (MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the appointment of Brian C. DeSchuytner as Senior Vice President of Finance and Product Strategy. Mr. DeSchuytner is an accomplished life science professional with nearly two decades of experience spanning corporate strategy, finance, product development, and commercial launch. Mersana also announced today the resignation of David A. Spellman as Chief Financial Officer, who has decided to pursue other opportunities.
- GlobeNewswire•17 days ago
Mersana Presents Interim Phase 1 Data for XMT-1536 at the 2019 American Society of Clinical Oncology Annual Meeting
Encouraging early signs of clinical efficacy Well tolerated with favorable safety profile in heavily pre-treated patient population CAMBRIDGE, Mass., June 01, 2019 --.
- GlobeNewswire•19 days ago
Mersana Therapeutics to Present at the Jefferies 2019 Global Healthcare Conference
CAMBRIDGE, Mass., May 30, 2019 -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of.
- GlobeNewswire•29 days ago
Mersana Therapeutics to Present Interim Phase 1 Data on XMT-1536 at the 2019 American Society of Clinical Oncology Annual Meeting
CAMBRIDGE, Mass., May 20, 2019 -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of.
Motley Fool•last monthMersana Therapeutics, Inc. (MRSN) Q1 2019 Earnings Call Transcript
MRSN earnings call for the period ending March 31, 2019.
- GlobeNewswire•last month
Mersana Therapeutics Announces First Quarter 2019 Financial Results and Provides Business Updates
Mersana Therapeutics, Inc. (MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today reported financial results and a business update for the first quarter ended March 31, 2019.
- GlobeNewswire•2 months ago
Mersana Therapeutics to Host Conference Call Announcing First Quarter 2019 Financial Results and Business Updates
CAMBRIDGE, Mass., May 02, 2019 -- Mersana Therapeutics, Inc., (NASDAQ:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of.
GuruFocus.com•2 months agoConsider These 3 Falling Knives
Further, these companies have a GuruFocus financial strength rating of at least 5 out of 10, reducing the bankruptcy rate risk, which is not uncommon among falling knives. Warning! GuruFocus has detected 2 Warning Signs with NCSM. The closing price on Friday was 4.1% off the 52-week low of $3.93 and 355% from the 52-week high of $18.6.
- GlobeNewswire•2 months ago
New Research: Key Drivers of Growth for Liberty Global, KKR Real Estate Finance Trust, AGCO, Model N, STAAR Surgical, and Mersana Therapeutics — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, April 09, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- GlobeNewswire•3 months ago
Mersana Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
CAMBRIDGE, Mass., April 01, 2019 -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of.
- GlobeNewswire•3 months ago
Mersana Therapeutics Announces Poster and Presentation at the American Association for Cancer Research Annual Meeting 2019
CAMBRIDGE, Mass., March 25, 2019 -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of.
- Simply Wall St.•3 months ago
What Should You Know About Mersana Therapeutics, Inc.’s (NASDAQ:MRSN) Earnings Trajectory?
The latest earnings update Mersana Therapeutics, Inc. (NASDAQ:MRSN) released in December 2018 indicated company earnings became less negative compared to the previous year's level - great news for investors Below,Read More...
- Benzinga•3 months ago
JPMorgan Downgrades Mersana, Says Data Readouts Unlikely To Reverse Street Sentiment
Mersana Therapeutics Inc (NASDAQ: MRSN ) shares, which went public in March 2018, was hit with its first bearish rating Monday in the absence of any stock-impacting data readouts over the next 12 months. ...
- GlobeNewswire•3 months ago
Mersana Therapeutics Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Business Updates
Company Plans to Report XMT-1536 Dose Escalation Data in the Second Quarter of 2019 Ended 2018 with $70 Million in Cash Further Strengthened Balance Sheet with Gross Proceeds.
- GlobeNewswire•3 months ago
Mersana Therapeutics to Present at the Cowen and Company 39th Annual Healthcare Conference
CAMBRIDGE, Mass., March 06, 2019 -- Mersana Therapeutics, Inc., (NASDAQ:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of.
- GlobeNewswire•3 months ago
Mersana Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Mersana Therapeutics, Inc., (MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the closing of its underwritten registered public offering of 24,437,500 shares of its common stock at the public offering price of $4.00 per share, which includes the exercise in full of the underwriters’ option to purchase additional shares of common stock. The shares of common stock described above were offered by Mersana pursuant to a shelf registration statement on Form S-3 (File No. 333-226055), which was declared effective by the Securities and Exchange Commission (SEC) on September 17, 2018. A preliminary prospectus supplement relating to and describing the terms of the offering was filed with the SEC on February 28, 2019.
- GlobeNewswire•4 months ago
Mersana Therapeutics to Host Conference Call Announcing Fourth Quarter and Year End 2018 Financial Results and Business Updates
CAMBRIDGE, Mass., March 01, 2019 -- Mersana Therapeutics, Inc., (NASDAQ:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of.
- Benzinga•4 months ago
The Daily Biotech Pulse: Puma Biotech Earnings, Mersana Offering, Orphan Drug Designation For Ascendis
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 28) Amphastar Pharmaceuticals Inc (NASDAQ: AMPH ) Abbott ...
- GlobeNewswire•4 months ago
Mersana Therapeutics Announces Pricing of Public Offering of Common Stock
Mersana Therapeutics, Inc. (MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet need, today announced the pricing of an underwritten public offering of 21,250,000 shares of common stock at a price to the public of $4.00 per share. In addition, Mersana has granted the underwriters a 30-day option to purchase up to an additional 3,187,500 shares of common stock, at the public offering price less underwriting discounts and commissions. Mersana intends to use the net proceeds from the offering to support clinical development of XMT-1536, to progress Mersana’s next ADC product candidates into Phase 1 clinical development, to progress Mersana’s early platform development and the balance to fund working capital, capital expenditures and other general corporate purposes.
- GlobeNewswire•4 months ago
Mersana Therapeutics Announces Proposed Public Offering of Common Stock
Mersana Therapeutics, Inc. (MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet need, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. As part of the offering, Mersana intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering, at the public offering price less underwriting discounts and commissions. Mersana intends to use the net proceeds from the offering to support clinical development of XMT-1536, to progress Mersana’s next ADC product candidates into Phase 1 clinical development, to progress Mersana’s early platform development and the balance to fund working capital, capital expenditures and other general corporate purposes.
- GlobeNewswire•4 months ago
Mersana Therapeutics to Present at the 8th Annual SVB Leerink Global Healthcare Conference
CAMBRIDGE, Mass., Feb. 20, 2019 -- Mersana Therapeutics, Inc., (NASDAQ:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of.
- American City Business Journals•5 months ago
Mersana CEO details path forward after breakup with Takeda
Mersana executives discussed data from its ovarian and lung cancer drug trial Wednesday. The biotech also plans to disclose its next clinical candidate in the second half of 2019.
- Simply Wall St.•5 months ago
Are Mersana Therapeutics, Inc.’s (NASDAQ:MRSN) Interest Costs Too High?
Mersana Therapeutics, Inc. (NASDAQ:MRSN), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is MRSN Read More...
- GlobeNewswire•5 months ago
Mersana Therapeutics Announces Strategic Priorities and Goals for 2019 and Beyond
Mersana Therapeutics, Inc., (MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet need, today announced that after a strategic evaluation the Company will prioritize its resources to focus on the advancement of XMT-1536, a first-in-class ADC candidate targeting NaPi2b. “While still in early clinical development, we are encouraged with the safety, tolerability, and activity of XMT-1536 as well as the pace at which the current study is advancing. For this reason, we have decided to focus our resources on advancing XMT-1536, our first-in-class ADC candidate targeting NaPi2b, a clinically validated ADC target broadly expressed in ovarian and non-small cell lung cancer (NSCLC) adenocarcinoma, for which there remains a significant unmet medical need,” said Anna Protopapas, President and CEO, Mersana Therapeutics.
